Introduction
Novel coronavirus disease (COVID-19) is a newly discovered contagious disease caused by SARS-CoV-2 virus, primarily manifesting as an acute respiratory illness with interstitial and alveolar pneumonia, but can affect multiple organs such as kidney, heart, digestive tract, blood and nervous system 1 . The rapidly spreading outbreak which first emerged in Wuhan, Hubei Province in China in December 2019 has raised concerns about a global pandemic. To date (2 March 2020), 88,948 cases of COVID-19 have been reported worldwide in 65 countries (and a cruise ship) and 79,842 in mainland China, with 3,043 deaths worldwide (mainland China 2,915 deaths). 2 SARS-CoV-2 has been identified as a bat-origin coronavirus (CoV). The full-length genome sequence of the COVID-19 virus showed a close relationship with the bat SARS-like coronavirus strain BatCov RaTG13 belonging to the Betacoronavirus genus. 3 Previous coronavirus infections, severe acute respiratory syndrome (SARS-CoV) and Middle East Respiratory Syndrome coronavirus (MERS-Co-V), have infected more than 10,000 people in the past 2 decades, with mortality rates of 10% and 37% respectively 4, 5 . COVID-19 is more contagious than these illnesses, spreads by human-to-human transmission via droplets, fecal or direct contact, and has an incubation period estimated at 1 to 14 days (usually 3 to 7 days).
Infection has been reported in all ages, including children. The majority of infections are mild, presenting with a flu-like illness. The common clinical presentations of COVID-19 are fever (98%), cough (76%), and myalgia and fatigue (18% each) 6 , with accompanying leucopenia (25%) and lymphopenia (63%). Symptoms of upper respiratory infection with rhinorrhea and productive cough are uncommon, except in children. About 16-20% cases have been classified as 'severe' or 'critical'. Of the 41 patients described by Huang et al 6 , all had pneumonia with abnormalities on computerized tomographic examination of the chest (bilateral lobular and subsegmental areas of consolidation), and 32% required ICU care.
Higher plasma cytokine levels (IL2, IL7, IL10, GSCF, IP10, MCP1, MIPIA, TNFα) were present in patients requiring ICU admission. Limited reports suggest that severe complications are uncommon in children. 7
Diagnosis
The diagnosis is mainly based on epidemiological factors (history of contact), clinical manifestations, and laboratory examination (hemogram, chest CT and virological examination, etc) 8 . Of note, there are recent cases without any travel history or apparent contact with infected individuals. Several COVID-19 nucleic acid detection assays have been developed, both in-house and commercial. They use fluorescence PCR, and probe anchoring polymerization technique. Gene sequencing has also been utilized. The World Health Organization has appointed several referral laboratories in different countries. 9 A serological test has been developed and allowed detection of a cluster of cases in Singapore 10 . More sensitive and convenient detection methods continue to be developed.
Kidney involvement in COVID-19 infection
In previous reports of SARS and MERS-CoV infections, acute kidney injury (AKI) developed in 5-15% cases and carried a high (60-90%) mortality. Early reports suggested a lower incidence (3-9%) of AKI in those with COVID-19 infection 1, [11] [12] [13] . Recent reports, however, have shown higher frequency of renal abnormalities. A study of 59 patients with COVID-19 found that 34% of patients developed massive albuminuria on the first day of admission, and 63% developed proteinuria during their stay in hospital 14 . BUN was elevated in 27% overall and two thirds of patients who died. CT scan of the kidneys showed reduced density, suggestive of inflammation and edema. Cheng et al 13 recently reported that amongst 710 consecutive hospitalized patients with COVID-19, 44% had proteinuria and hematuria and 26.7% had hematuria on admission. The prevalence of elevated Scr and BUN were 15.5% and 14.1% respectively. AKI was an independent risk factor for patients' in-hospital mortality 13, 14 .
Pathogenesis of kidney injury
The exact mechanism of kidney involvement is unclear: postulated mechanisms include sepsis leading to cytokine storm syndrome or direct cellular injury due to the virus.
Angiotensin converting enzyme and dipeptidyl peptidase 4, both expressed on renal tubular cells, were identified as binding partners for SARS-CoV and MERS-CoV respectively 15, 16 .
Viral RNA has been identified in kidney tissue and urine in both infections 17, 18 . Recently, Zhong's lab in Guangzhou has successfully isolated SARS-CoV-2 from the urine sample of an infected patient, suggesting the kidney as the target of this novel coronavirus 19 .
Treatment
The current treatment of COVID-19 with AKI includes general and supportive management, and kidney replacement therapy. There is no effective anti-viral therapy available at present.
General management
All the patients with confirmed COVID-19 should be quarantined. A N-95 fit-tested respirator and protective clothes and equipment are essential. Early admission to ICUs in designated hospitals is recommended for severely ill patients.
Supportive care, namely bed rest, nutritional and fluid support, maintenance of blood pressure and oxygenation are important measures, as for all critically ill patients. Other measures include prevention and treatment of complications by providing organ support, maintaining hemodynamic stability and prevention of secondary infection.
Antiviral therapy
There is no specific effective antiviral drug for COVID-19 at present. The guidelines of the Chinese National Health Commission recommend aerosolized inhalation of interferonα, and Lopinavir/Ritonavir. The specific therapeutic value and safety of Lopinavir/Ritonavir in COVID-19 patients is under investigation (ChiCTR2000029308) 20 . Successful treatment with remdesivir has been reported in a COVID-19 patient; a clinical trial on the efficacy of remdesivir in COVID-19 patients is currently underway in China (NCT0425266; NCT04257656)and is expected to be completed in April 2020. Chloroquine phosphate has been shown to have some efficacy against COVID-19 associated pneumonia in multicenter clinical trials conducted in China. 21 
Extracorporeal treatments
CRRT has been successfully applied in the treatment of SARS, MERS and sepsis 22, 23 . Highvolume hemofiltration (HVHF) in a dose of 6L/hr removed inflammatory cytokines (IL-6) and improved the SOFA (Sequential Organ Failure Assessment) scores at day 7 in patients with sepsis 24 . Therefore, CRRT may play a role in patients with COVID-19 and sepsis syndrome. The potential role of extracorporeal therapy techniques needs to be evaluated, however.
Glucocorticoids
In a retrospective study of patients with SARS-CoV and sepsis, steroids, in a mean daily dose of 105.3 +/-86.1 mg in 147 of 249 noncritical patients (59.0%) reduced mortality and shortened duration of hospitalization, while 121 of 152 critical patients (79.6%) received corticosteroids at a mean daily dose of 133.5 +/-102.3 mg, and 25 died 25 . A subsequent retrospective observational study of 309 MERS patients showed that those who received high dose steroids were more likely to require mechanical ventilation, vasopressors and RRT 26 . In a metanalaysis of corticosteroid use in SARS patients, 4 studies provided conclusive evidence of harm (psychosis, diabetes, avascular necrosis and delayed viral clearance) 27 . Therefore, the use of steroids is controversial and not recommended by WHO due to potential inhibition of viral clearance and prolongation of the duration of viremia 28 .
Convalescent plasma
Preliminary clinical studies in China have shown that early application of convalescent plasma in patients with COVID-19 could accelerate clinical recovery 6 
Monoclonal antibody
Monoclonal antibody directed against the RBD domain of the S protein of MERS-CoV has been found to have neutralizing activities in plaque assays in vitro. 29 A monoclonal antibody against COVID- 19 has not yet been developed. Trastuzumab, a monoclonal antibody against the IL-6 receptor, has achieved encouraging preliminary clinical results. The safety and efficacy of Trastuzumab in COVID-19 infection is undergoing evaluation by a multicenter randomized controlled trial (ChiCTR2000029765).
COVID-19 in patients with kidney disease
Pregnant women, newborn and the elderly, and patients with comorbidities like diabetes mellitus, hypertension, cardiovascular disease are susceptible to COVID-19 infection and likely to have more severe illness often requiring ICU care. The impact of COVID-19 on CKD has not been reported 30 . Operational strategies for family member and caregivers
COVID-19 infection presents

1.
All the family members living with dialysis patients must follow all the precautions and regulations given to patients to prevent person-to-person and within family transmission of the COVID-19, which include body temperature measurement, good personal hygiene, handwashing, and prompt reporting of potentially sick people.
2.
Dialysis patients, who have a family member or caregiver subject to "basic quarantine", can have dialysis as usual in accordance during the 14-day period.
3.
Once the family members or caregiver of dialysis patients have been converted to a confirmed case, the patient's identity should be upgraded and treated in accordance with the above-mentioned conditions.
In summary, COVID-19, a disease caused by a novel coronavirus, is a major global human threat with a potential to turn into a pandemic. Kidney involvement seems to be frequent in this infection and AKI is an independent predictor of mortality. The impact of this infection in those with CKD has not been studied, and the management of patients on dialysis who have been suspected to have been in contact with COVID-19 should be carried out according to strict protocols to minimize risk to other patients and healthcare personnel taking care of these patients.
